Octreotide LAR in carcinoid: how to dose?
Yao
James C
JC
Kvols
Larry K
LK
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000378:metabolism; D015282:Octreotide / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000378:metabolism; D012107:Research Design; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; C093733:somatostatin receptor 2; D015282:Octreotide